The Food and Drug Administration on Wednesday approved daraxonrasib for advanced pancreatic cancer, clearing a new option that the agency says can extend life. The medicine, which will be sold as Rasonque, is made by Revolution Medicines.
What makes the decision notable is not just the approval itself but the fact that daraxonrasib is described as the first drug to attack a genetic cause of pancreatic cancer. In a disease known for moving fast and leaving few good options, that alone marks a sharp break from older treatment patterns.
The approval was backed by a clinical trial that read out earlier this year. In that study, patients with advanced pancreatic cancer who received Rasonque as a second-line treatment had a median overall survival of 13.2 months, compared with 6.7 months for those offered standard chemotherapy. That gap is the kind of result that can change how doctors think about a hard-to-treat cancer, especially when the treatment is being used after an earlier therapy has not worked.
Andrew Ko called the approval transformative and said it was the biggest development in pancreas cancer in decades. He also said, “I’m so thankful for this as an advance for our patients.” That reaction fits the scale of the result, but it also points to the limit built into the approval: this is for advanced pancreatic cancer in the second-line setting, not a cure for all patients with the disease.
That narrow use matters. The drug is being introduced into one of the most difficult corners of pancreatic cancer care, where patients have already gone through an earlier treatment and need another option quickly. For now, the question is not whether daraxonrasib is a major step forward. It is how far that step will reach once doctors begin using Rasonque beyond the trial that helped secure the approval.
